ALFA Finder
Thu, 5 Nov
Influx Healthtech
Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
Summary ready
Earnings calls
Influx Healthtech concalls
Every Influx Healthtech earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
Outlook
Guides 25% FY27 growth, but the new plant is only 'a couple of months' from operational. Its H2 contribution (~20%) is hedged and conditional on licensing.
Earlier call summaries
All →
17:53 IST
NSE
Earnings Call
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech reported FY26 revenue of ₹146cr, a 41% YoY increase, with PAT at ₹20.5cr. Strategy focuses on scaling nutraceutical CDMO capacity by 2.5x through a new 75,000 sq ft facility.
19:09 IST
NSE
Earnings Call
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech delivered strong 41% YoY revenue growth in H2 FY26, driven by nutraceuticals, despite margin pressure from aggressive hiring ahead of massive capacity expansion.
17:30 IST
NSE
Earnings Call
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech delivered strong FY26 performance as a specialist CDMO in nutraceuticals and cosmetics, focusing on capacity expansion and new technology implementation following its 2025 NSE listing.
Influx Healthtech Limited: key numbers
- Share price
- ₹251.00
- Market cap
- ₹581.1 Cr
- Revenue (annual)
- ₹146.8 Cr
- Net profit (annual)
- ₹20.54 Cr
- P/E (TTM)
- 28.3×Sector 43.0×
- Promoter holding
- 73.53%
- FII holding
- 0.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.